The label expansion for Boehringer Ingelheim’s Hernexeos was made under an FDA pilot program that accelerates regulatory review of products with national interest. The daily pill is now approved as a first-line treatment for HER2-positive non-small lung cancer, an indication with few treatment options.
The post FDA Voucher Leads to Speedy Approval of Boehringer Drug for First-Line Use in Lung Cancer appeared first on MedCity News.
Cisco says hackers have been exploiting a critical bug to break into big customer networks since 2023
Zack Whittaker reports: Cisco says hackers have been exploiting a bug in one of its popular networking products used by large enterprises for at least
